Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Anne T. M. Dittrich"'
Autor:
Karlijn Bouman, Jan T. Groothuis, Jonne Doorduin, Nens van Alfen, Floris E. A. Udink ten Cate, Frederik M. A. van den Heuvel, Robin Nijveldt, Willem C. M. van Tilburg, Stan C. F. M. Buckens, Anne T. M. Dittrich, Jos M. T. Draaisma, Mirian C. H. Janssen, Erik-Jan Kamsteeg, Esmee S. B. van Kleef, Saskia Koene, Jan A. M. Smeitink, Benno Küsters, Florence H. J. van Tienen, Hubert J. M. Smeets, Baziel G. M. van Engelen, Corrie E. Erasmus, Nicol C. Voermans
Publikováno v:
BMC Neurology, Vol 21, Iss 1, Pp 1-14 (2021)
Abstract Background SELENON (SEPN1)-related myopathy (SELENON-RM) is a rare congenital myopathy characterized by slowly progressive proximal muscle weakness, early onset spine rigidity and respiratory insufficiency. A muscular dystrophy caused by mut
Externí odkaz:
https://doaj.org/article/99f6f067662b4ae7948d3919fc82048d
Autor:
Anne T. M. Dittrich, Etienne J. M. Janssen, Joyce Geelen, Karlijn Bouman, Leanne M. Ward, Jos M. T. Draaisma
Publikováno v:
Applied Sciences, Vol 13, Iss 7, p 4491 (2023)
By definition, children constitute a vulnerable population, especially when they are chronically ill and/or disabled. A characteristic of chronically ill and disabled children is that they also suffer from indirect effects of their disease, such as i
Externí odkaz:
https://doaj.org/article/82d755aaabd84756879ee2c97f8e5513
Autor:
Anne T. M. Dittrich, Nori J. L. Smeets, Emma F. M. de Jong, Juliët L. Kämink, Yvet Kroeze, Jos M. Th. Draaisma, Eugène P. van Puijenbroek, D. Maroeska W. M. te Loo
Publikováno v:
Pharmaceuticals, Vol 15, Iss 9, p 1148 (2022)
For drug safety in pediatric patients, knowledge about adverse drug reactions (ADRs) is essential to balance benefits and risks, especially because of the high incidence of off-label drug use. However, underreporting of ADRs is a serious problem, lea
Externí odkaz:
https://doaj.org/article/148aef8c56994023940649287268e2a6
Autor:
Nadieh A. Jansen, Anne T M Dittrich, Manouk Backes, Benno Kusters, Willemijn M Klein, Tim Hundscheid
Publikováno v:
BMC Pediatrics, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Two cases of neonatal splenic hemorrhage with acute cardiorespiratory failure are described in this report. The first case involves a full-term neonate who was found unresponsive without any witnesses and could not be successfully resuscitat
Externí odkaz:
https://doaj.org/article/4fd0c77e5aa54f85aafd8c13063894c4
Autor:
Carlien A. M. Bennebroek, Judith van Zwol, Giorgio L. Porro, Rianne Oostenbrink, Anne T. M. Dittrich, Annabel L. W. Groot, Jan W. Pott, Etienne J. M. Janssen, Noël J. Bauer, Maria M. van Genderen, Peerooz Saeed, Maarten H. Lequin, Pim de Graaf, Antoinette Y. N. Schouten-van Meeteren
Publikováno v:
Bennebroek, C A M, van Zwol, J, Porro, G L, Oostenbrink, R, Dittrich, A T M, Groot, A L W, Pott, J W, Janssen, E J M, Bauer, N J, van Genderen, M M, Saeed, P, Lequin, M H, de Graaf, P & Schouten-van Meeteren, A Y N 2022, ' Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma : A Retrospective Nationwide Multicentre Study ', Cancers, vol. 14, no. 24, 6087 . https://doi.org/10.3390/cancers14246087
Cancers, 14(24):6087. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 14
Cancers; Volume 14; Issue 24; Pages: 6087
Cancers, 14(24):6087. MDPI AG
Cancers, 14, 24
Cancers, 14(24):6087. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 14
Cancers; Volume 14; Issue 24; Pages: 6087
Cancers, 14(24):6087. MDPI AG
Cancers, 14, 24
BACKGROUNDS: Bevacizumab (BVZ) is used as a subsequent line of treatment for pediatric optic pathway glioma (OPG) in the case of progression. Data on the treatment effect concerning tumor progression and visual function are scarce and nationwide stud
Autor:
Jos M. T. Draaisma, Jonne Doorduin, Nicol C. Voermans, Florence H J van Tienen, Hubert J.M. Smeets, Baziel G.M. van Engelen, Jan A.M. Smeitink, Nens van Alfen, Saskia Koene, Benno Küsters, Willem C M van Tilburg, Mirian C. H. Janssen, Floris E A Udink Ten Cate, Corrie E. Erasmus, Robin Nijveldt, Anne T. M. Dittrich, Karlijn Bouman, Frederik M. A. van den Heuvel, Jan T. Groothuis, Stan Buckens, Esmee S.B. Van Kleef, Erik-Jan Kamsteeg
Publikováno v:
BMC Neurology, Vol 21, Iss 1, Pp 1-14 (2021)
BMC Neurology, 21
BMC Neurology
BMC Neurology, 21, 1
BMC Neurology, 21(1):313. BioMed Central Ltd
BMC Neurology, 21
BMC Neurology
BMC Neurology, 21, 1
BMC Neurology, 21(1):313. BioMed Central Ltd
BackgroundSELENON (SEPN1)-related myopathy (SELENON-RM) is a rare congenital myopathy characterized by slowly progressive proximal muscle weakness, early onset spine rigidity and respiratory insufficiency. A muscular dystrophy caused by mutations in
Publikováno v:
Bone Reports, Vol 14, Iss, Pp 100991-(2021)
Publikováno v:
Paediatric drugs, 22(4), 425-432. ADIS INT LTD
Paediatric Drugs
Paediatric Drugs, 22, 425-432
Paediatric Drugs, 22, 4, pp. 425-432
Paediatric Drugs
Paediatric Drugs, 22, 425-432
Paediatric Drugs, 22, 4, pp. 425-432
Contains fulltext : 229840.pdf (Publisher’s version ) (Open Access) AIMS: The risk to develop adverse drug reactions (ADRs) is high for paediatric patients. This is, amongst other reasons, due to the inevitable use of off-label and unlicensed medic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7370cad86bebe7c4a7e92eb6287a7fb
https://research.rug.nl/en/publications/eb1ed801-889e-4242-8bfc-85207a6da6a5
https://research.rug.nl/en/publications/eb1ed801-889e-4242-8bfc-85207a6da6a5
Autor:
Corrie E. Erasmus, Jan T. Groothuis, Robin Nijveldt, Anne T. M. Dittrich, E. van Kleef, B.G.M. van Engelen, Mirian C. H. Janssen, Karlijn Bouman, E. Kamsteeg, F. van Tienen, Jonne Doorduin, Stan Buckens, H. J. M. Smeets, Jan A.M. Smeitink, F. Udink ten Cate, Jos M. T. Draaisma, F. van den Heuvel, Nicol C. Voermans, W. van Tilburg, N. van Alfen
Publikováno v:
Neuromuscular Disorders. 31:S70
Publikováno v:
Bone Reports, Vol 14, Iss, Pp 100977-(2021)